Categories: All postsSpace

Skies remain dark for Maxar Technologies, this portfolio manager says

Shares of Maxar Technologies (Maxar Technologies Stock Quote, Chart TSX:MAXR) popped last week on good news regarding an insurance payout, but is the stock still a buy? Not likely, says Rick Stuchberry of Wellington-Altus Private Wealth, who admits that he made a mistake in holding onto it.

“We used to own this thing a year or two ago. We held on too long when it got into trouble. We did exit it — it’s one of those things where you say, well, when do I cut and run and when do I stay?” says Stuchberry, in conversation with BNN Bloomberg on Monday. “We just couldn’t see light at the end of the tunnel.”

Maxar Technologies announced last week that its insurance carriers had accepted the full $183-million claim for the loss of its WorldView-4 satellite, which in January of this year was found to have an irreversible defect, a major blow, as the image satellite was to be a prime money-maker for the company. Management says that it will use the funds to invest in its pre-existing capital priorities, which include its WorldView Legion constellation of satellites scheduled to replace three of its older models. (All figures in US dollars.)

The market reacted positively to the news, bumping up the stock by 36 per cent over the past few trading days. Last year, Maxar’s share price started to nose dive in July as investors responded to a number of issues befalling the company, including a write-down of its satellite business and a short-seller attack. The start of 2019 proved to be no better, with the loss of the satellite and the departure of its CEO both coming in January.

Stuchberry says there might be a turnaround in store, but it’s tough to call.

“We recognized that we made a mistake and exited, took our money and redeployed it in different areas. [But] if you think there’s light at the end of the tunnel here, then you could hold or even add some,” he says.

Ahead of Maxar’s quarterly results due on Thursday, Maxar’s last quarter was reported on February 28, where it posted fourth quarter revenue of $496 million, which came in below analysts’ average forecast of $560.3 million, along with a net loss of $950 million or $16.10 per share.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: maxr
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

6 hours ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

8 hours ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

8 hours ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

1 day ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

1 day ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

1 day ago